Toronto, Ontario – December 7, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that the University of British Columbia (“UBC”) Review Ethics Board (“REB“) has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (“CIS“) and who are considered Bacillus Calmette Guerin(“BCG“)-Unresponsive or are intolerant to BCG Therapy (“Study II“). The University of British Columbia is a global center for teaching, learning and research, consistently ranked among the top 20 public universities in the world and recently recognized as North America’s most international university.   To date 14 patients have been treated in Study II.  With the addition of UBC, the … Read More

Toronto, Ontario – November 27, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamicCompounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 3Q2020 financial statements. Financial Highlights: For the nine-month periods ended September 30: Unaudited Condensed Consolidated Statements of Operations            In Canadian Dollars     2020 2019 % Change  Revenue       Canada 449,359 477,502 -6% United States 52,074 23,926 +117% International 26,041 13,463 +93% Total Revenue 527,474 514,891 +2%         Cost of Sales 383,990 374,070 +3% Gross Margin 143,484 140,851 +2% Gross Margin as a percentage of sales 27% 27% 0%         Operating Expenses       Selling Expenses 333,863 505,914 -34% Administrative Expenses 1,522,179 1,798,682 -15% Research and Development Expenses – CLT Division 259,507 401,511 -35% Research and Development … Read More

Toronto, Ontario –November 23, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that the U.S. Food and Drug Administration (“FDA”) has granted Theralase® Fast Track Designation (“FTD”) for its Phase II Bacillus Calmete Guérin (“BCG”)–Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In Situ (“CIS”) clinical study (“Study II”). As a Fast Track designee, Theralase® will have access to early and frequent communications with the FDA to discuss Theralase’s development plans and ensure timely collection of the appropriate clinical data to support the approval process. The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system (“TLC-3200”), to be the first intravesical patient-specific Ruthenium-based PDC for the treatment of patients with BCG-Unresponsive NMIBC CIS, with … Read More

Toronto, Ontario – November 13, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that its PDC technology has demonstrated a high kill rate in a preclinical analysis of coronavirus, Biological Safety Level (“BSL-2”). Theralase previously reported that the Company’s  PDC technology was effective in the destruction of Influenza H1N1 and Zika viruses at low nanomolar concentrations.  These studies were  expanded to include coronavirus (BSL-2). As a note, COVID-19 is caused by coronavirus (BSL-3), not coronavirus (BSL-2). An assay was established to measure coronavirus destruction and using this new assay the Theralase® PDC technology was able to destroy coronavirus (BSL-2) with drug doses 5 times lower than what was used to kill Influenza H1N1 and Zika viruses. These drug doses … Read More

Toronto, Ontario – October 26, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company“)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC“) and associated drug formulations has released the Company Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study. The Newsletter can be found on the Company’s website www.theralase.com/quarterly-newsletters/. To receive future Newsletters, please contact info@theralase.com. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Additional information is available at www.theralase.com and www.sedar.com Forward Looking Statement This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and … Read More

Toronto, Ontario – September 30, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the “Warrants“). The Warrants were issued on October 3, 2018 pursuant to a private placement involving the issuance of 3,157,059 units of the Company. The Company proposes to extend the expiry date of the Warrants that remain outstanding from the original expiry date of October 3, 2020 to October 3, 2022. All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc. Theralase® is … Read More

Toronto, Ontario – September 24, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that McGill University Health Centre (“MUHC”) has re-commenced new patient enrollment and treatment in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment. Efficacy to date at the 90 day assessment includes: 3 out of 12 patients (25%) have demonstrated a Complete Response (“CR”) … Read More

Toronto, Ontario – August 28, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses released its unaudited interim consolidated condensed 2Q2020 financial statements. Financial Highlights: Total revenue for the six-month period ended June 30, 2020, decreased to $293,453 from $370,436 for the same period in 2019, a 21% decrease. In Canada, revenue decreased 23% to $255,146 in 2020 from $333,047 in 2019. In the US, revenue decreased 49% to 12,267 in 2020 from $23,926 in 2019. International revenue increased 93% to $26,041 for 2020 from $13,463 in 2019. The decrease in total revenue in 2020 is primarily attributed to the COVID-19 pandemic as a majority of health care practitioners elected to temporarily close their … Read More

Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses, announced today that the board of directors of Theralase has approved amendments to the Company’s standard by-laws. The amendments to the Company’s standard by-laws include certain housekeeping amendments and updates to the general by-laws in order to better align with the current provisions of the Canada Business Corporations Act and corporate governance standards.  The amended by-laws remain subject to the approval of the TSX Venture Exchange and will be put before shareholders at the Company’s upcoming annual and special meeting of shareholders to be held on September 24, 2020 for approval. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the … Read More

Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that it has executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing Theralase’s patented and proprietary PDCs. According to the SRA, UM will conduct experiments in conjunction with Theralase for the research and development of a coronavirus vaccine and therapeutic to be further evaluated in animal then human clinical testing in 2021. Dr. Kevin Coombs, PhD, Professor, Department of Medical Microbiology, will lead the research for the University of Manitoba. One of Dr. Coombs’ interests is the investigation of how COVID-19 impacts genes and proteins in lung cells. In … Read More